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Background - Why? 
• Why is this of interest when current therapy 
has dramatically altered the course of HIV? 
– Long term complications of ART 
– Can ART be taken indefinitely 
• Strategies to deal with ART complications 
– simplification  
– switch 
– ART interruption (STI, i-ART) 
• “Structured” implies understanding? 
Background - Initial Reports 
• Interruption: Viral load returns to baseline 
after long term suppression. 
– Rapid return to baseline (Jubault, AIDS 98 & 
Staszewski, AIDS 98) 
– Intermittent ART lead to increased time to 
rebound (n=3) (Lori, 6th CROI) 
– COMET: Rapid return to baseline but no 
deleterious effect after re-initiation (n=10)  
(Neumann, AIDS 99) 
– Increase of ~0.2 log10 in total viral burden/day 
(n=6) (Harrigan, AIDS 99) 
Background - Recent Studies 
• Prospective study (n=8) all returned to baseline 
(doubling time = 2.01 days) and all re-suppressed. 
No viral drug resistance. (Garcia, AIDS 99) 
• Some patients remain suppressed or, after initial 
rebound, decline toward level of  quantification. 
– “Berlin patient” (Lisziewicz NEJM 99) 
– Long term suppression in PHI (n=4) doubling time ~ 
1.6 days. 3/4 peaked at 4.32 log10 and declined to 3.53 
log10 (Markowitz, ICAAC 99, LB16) 
– NoHRT study 12/18 received IL-2. 1/18 has VL 50 - 
500. (Davey, ICAAC 99, I-689) 
Background - Immunology 
• Protective cellular immunity returns after ART 
– Discontinuation of PCP Prevention (Lopez, ICAAC 99 LB24) 
• HIV antibody response 
• CD8 cytotoxic response (CTL) 
• HIV-specific CD4 response strong in long term 
non-progressors 
– may be present in many patients but significantly 
decreases after PHI. Wanes with ART (Pitcher, Nat Med 
99) 
– Is there sufficient antigen present in patients with viral 
load BLQ and restored immune system? 
Working Hypothesis 
Patients with long-term viral suppression and 
a significant increase in CD4 T-cells, should 
have an increase in naïve CD4 T-cells. 
Naïve CD4 cells should be able to “respond” 
to HIV antigen during initial interruption. 
Subsequent ART interruption may result in a 
reduction of rebound viral load (reduced set 
point) due to immunologic control of HIV. 
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Methods 
• A retrospective analysis of 268 patient 
charts (N ~ 500) to identify patients who 
interrupted ART. 
• 123 (45.9%) interrupted ART at least once. 
36 had baseline and follow-up data. 
– 23 had data for an initial interruption.  
– 18 had data for a subsequent interruption. 
– 5 had data for initial and subsequent 
interruptions (overlap) 
Methods 
• Charts examined for: 
– Composition and duration of ART regimen. 
– Duration viral load was BLQ (< 50 mid-1997.) 
– Change in CD4 levels on ART. 
– Reason(s) for interruption. 
– Duration of interruption. 
– Change in viral load. 
ART Interruption - Why? 
• Common event in clinical practice 
• Why do patients interrupt ART? 
– Rule One, All or None! 
• Reasons for interruption: 
– Side Effects 
– Ran Out of Meds 
– Active Drug Use 
– No Insurance 




– Difficulty Eating 
– Leaving U.S.A. 
– RTV Oral Solution 
– Patient Choice 
Return to Baseline After First Interruption 
VL* 
– n = 23‡ 
– Mean = +0.059 log10 
– Median = +0.028 log10 
– Standard Deviation = 0.35 log10 
 
VL at longest duration of interruption used for each patient 
‡ Patients #81 and #104 were not included in calculations 
due to unquantified results (> upper limit of test). 
  
Effect of Duration of First Interruption 
on VL 
Slope = 1.64 x 10-4 
Standard Error of Linear Regression = 0.480 log10 copies 





Duration BLD Reason for
Interruption
70 2 AZT/3TC/NFV 264 132 (<25) + 92
(<400)
Depression
79 3 D4T/3TC/NVP 84 0 Viral Failure
27 4 AZT/3TC/NFV/SQV 91 40 (<500) N/V
12 2 D4T/3TC/NVP 486 266 (<400) +
192(<50)
Drug Use
30* 4 NFV/SQV 5 0 Pt. Choice
23 2 D4T/3TC/RTV/SQV 278 255 (<200) Not Tolerating
RTV Solution
67* 2 AZT/3TC/RTV/SQV 8 0 Ran Out
69 3 D4T/3TC/RTV/SQV 23 0 Abdominal
Enlargement
Interruption resulting in largest VL is shown.
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Duration BLD Reason for
Interruption
77 2 D4T/3TC/NVP 43 >1 (<400) Fatigue
15 3 DDI/3TC/NVP 231 126 (<50) Left USA
14 3 D4T/3TC/NFV 273 89 (<400) Oral Cancer
54 4 D4T/3TC/RTV/SQV 76 14 (<400) ?




24 2 AZT/3TC/NVP 348 99 (<400) +
217 (<50)
Noncompliance
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Return to Baseline After Subsequent Interruptions: 
Responders (10/18) 
Pt # Inter # Duration CD4 VL
108 3 39 +273 -1.39
70 2 153 +245 -1.21
79 3 25 +219 -1.10
27 3 86 +333 -1.09
12 2 109 +199 -1.06
30 4 70 +92 -1.06
107 6 21 +194 -1.03
23 2 57 +314 -0.93
67 2 21 +80 -0.86
112 2 112 +151 -0.72
Return to Baseline After Subsequent Interruptions: 
Non-Responders (8/18) 
Pt # Inter # Duration CD4 VL
69 3 49 0 -0.61
113 2 73 0 -0.54
77 2 69 +136 -0.46
15 3 92 +72 -0.34
14 3 86 +46 -0.33
54 4 106 +10 -0.22
25 2 77 +5 0.00
24 2 71 +27 +0.58
• Slope = -3.26 x 10-3 
• Standard Error of Linear Regression = 0.659 log10 copies 
Effect of CD4 on VL for Subsequent 
Interruptions 
Effect of CD4 on VL for Subsequent 
Interruptions 
Summary: Subsequent Interruptions (n=18) 
• Virologic Response (At longest duration of interruption.) 
– 10/18 (56%) “reset” set point > 0.70 log10 below baseline 
viral load for 21 - 153 days. 4/10 reset > 1.0 log10 for > 
70 days. (6/10 on PI 
• CD4 Response (prior to interruption) 
– Responders (10/18): average CD4 cell increase = 210 
(95% CI: 149, 271) 
– Non-Responders (8/18): average CD4 increase = 37 
(95% CI: -2, 76) 
– absolute CD4 does not appear to correlate 
• 6/10 responders on PI, 3/8 non-responders on PI 
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Note: DJ <5000 @ 3 months during 4th interruption 
  
Response to ART Interruption 
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Note: LG <5000 @ 3 months during 4th interruption 
Reduction of Viral Set Point - Why?  
• With the return of HIV-naïve T-cells, the first 
interruption may result in HIV “vaccination.”  
• If ART restarted before these cells are lost, HIV-
specific responses should be retained. 
• A second ART interruption may stimulate HIV-
specific proliferative responses with reduction in  
viral rebound (reduced set point). 
• By preventing depletion of HIV-specific CD4 T-
cells during interruption, successive interruptions 
may result in further set point reduction. 
Alternative Explanations 
• Type I error - this is a small retrospective 
analysis with limited data points. 
• Original virus replaced with a less fit virus. 
• Original set point not accurately determined. 
• Laboratory variation and error 
• Further analysis of the entire cohort is 
planned 
Conclusions - Questions 
• Randomized, controlled trials are required to 
answer the following questions: 
– How is balance maintained between activated HIV-
specific CD4 cells (target) and virus? 
– What is the optimal duration of ART interruption? 
– OR, What is the optimal VL rebound?  (BOTH?) 
– Is the response different between PI and NNRTI? 
– What are the predictive immunologic parameters? 
– Will this be an “insurance policy” for occasional 
non-adherence? 
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